Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN52623943
ISRCTN52623943
Completed
未知

High Dose Therapy in Poor-Risk Primary Breast Cancer

Amgen Limited (UK)0 sites0 target enrollmentAugust 19, 2002
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsBreast cancerCancerBreast

Overview

Phase
未知
Intervention
Not specified
Conditions
Breast cancer
Sponsor
Amgen Limited (UK)
Status
Completed
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 19, 2002
End Date
September 28, 2001
Last Updated
6 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
Amgen Limited (UK)

Eligibility Criteria

Inclusion Criteria

  • •1\. Complete prior resection of tumour and axillary node clearance
  • •2\. Histologically proven T1\-T4 primary breast cancer with at least four involved nodes in the axilla
  • •3\. Adequate local therapy as defined in the protocol
  • •4\. Aged \<60 years
  • •5\. No previous malignancy or evidence of metastatic disease
  • •6\. Fit to receive treatment

Exclusion Criteria

  • •Not provided at time of registration

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Epirubicin/Paclitaxel/Cyclophosphamide-Methotrexate-Fluorouracil (E-T-CMF) as adjuvant chemotherapy in high-risk patients with operable breast cancerBreast CancerCancer - Breast
ACTRN12615000161527Hellenic Cooperative Oncology Group1,000
Completed
Not Applicable
Investigation of the prognostic role of protein expression, mRNA levels, gene amplification and mutation of key cellular elements in patients with breast cancer treated with dose-dense sequential adjuvant chemotherapyBreast CancerCancer - Breast
ACTRN12616001043426Hellenic Cooperative Oncology Group1,060
Completed
Phase 3
Epirubicin-Paclitaxel-Cyclophosphamide Methotrexate Fluorouracil (E-T-CMF) versus Epirubicin-Cyclophosphamide Methotrexate Fluorouracil (E-CMF) as adjuvant chemotherapy in high risk patients with operable breast cancer. A phase III study conducted by the Hellenic Cooperative Oncology Group (HE10/97)
ACTRN12611000506998Hellenic Cooperative Oncology Group600
Recruiting
Phase 2
Partial Breast Radiotherapy in Low-risk Breast cancer group using a stereotactic MR-guided adaptive approach; a phase II study
NL-OMON45437Vrije Universiteit Medisch Centrum50
Recruiting
Not Applicable
Partial Breast Radiotherapy in Low-risk Breast cancer group using a MR-guided adaptive approach; a phase II study
NL-OMON26191Amsterdam UMC, location VUmc50